Pimavanserin
71 interactions 3 explained in plain EnglishPimavanserin is used to treat hallucinations and delusions in people with psychosis from Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Pimavanserin is in a class of medications called atypical antipsychotics. It works by changing the acti… Read the full Pimavanserin drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Pimavanserin Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Pimavanserin Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Pimavanserin Ivabradine Corlanor An increased risk of QT interval prolongation Details Pimavanserin Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Pimavanserin Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Pimavanserin Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Pimavanserin Levofloxacin Levaquin An increased risk of QT interval prolongation Details Pimavanserin Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Pimavanserin Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Pimavanserin Mefloquine Lariam® An increased risk of QT interval prolongation Details Pimavanserin Metronidazole Flagyl An increased risk of QT interval prolongation Details Pimavanserin Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Pimavanserin Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Pimavanserin Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Pimavanserin Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Pimavanserin Moxifloxacin Avelox An increased risk of QT interval prolongation Details Pimavanserin Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Pimavanserin Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Pimavanserin Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation Details Pimavanserin Nafcillin Injection Unipen® Injection Reduced pimavanserin exposure and reduced efficacy of pimavanserin Details Pimavanserin Octreotide Bynfezia An increased risk of QT interval prolongation Details Pimavanserin Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Pimavanserin Ofloxacin Floxin® An increased risk of QT interval prolongation Details Pimavanserin Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Pimavanserin Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Pimavanserin Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Pimavanserin Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist